Most patients with diffuse large B-cell lymphoma (DLBCL) are> 65 years of age, with the
number of patients expected to increase in the coming years. A comprehensive geriatric …

Abstract The Elderly Prognostic Index (EPI) is based on the integration of a simplified
geriatric assessment, hemoglobin levels and International Prognostic Index and has been …

The prognosis for mantle cell lymphoma (MCL) remains poor. Our aim was to assess the
impact of comorbidities on survival and causes of death. For 1,385 MCL patients (1,009 …

Despite bendamustine-rituximab (BR) showed disappointing efficacy in diffuse large B cell
lymphoma (DLBCL), it is still occasionally used as first-line treatment in older DLBCL …

Summary Metronomic-chemotherapy (M-CHT) has been rarely assessed in non-Hodgkin-
lymphoma (NHL). Therefore, in 2011 we started experimenting a new all-oral M-CHT …

Although the current standard of care for diffuse large B-cell lymphoma (DLBCL) is six cycles
of rituximab/cyclophosphamide/doxorubicin/vincristine/prednisolone combination …

Morbidity and mortality during chemotherapy in older adults with haematological malignancy
can be unpredictable. The Haemato‐Oncology Frailty (HOF) score was previously found to …

Background The actual relative dose intensity (RDI) of the attenuated R-CCOP regimen
(rituximab, cytoxan, pegylated liposomal doxorubicin [PLD], vincristine, and prednisone) has …

Background A combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and
prednisone (R-CHOP) is considered the standard treatment for diffuse large B-cell …

Interventions: Chemotherapy. Outcomes: The patient eventually gave up and died of severe
infection. Lessons: Although intensive chemotherapy has markedly improved the survival of …